Akero, 89bio disclose public offerings; BioAge drops Phase 2 obesity drug

Plus, news about Vigonvita Life Sciences and Lutris Pharma: For MASH developers, a race for cash: Akero Therapeutics aims to raise $300 million in an offering that was announced the same ...